H. Wilkens (Homburg/Saar, Germany), M. D'Alto (Naples, Italy), C. Opitz (Berlin, Germany), D. Kiely (Sheffield, United Kingdom)
Combination of sPESI and cardiac troponin in the outpatient treatment of pulmoner thromboembolism
S. Ozsu, H. Bektas, Y. Abul, T. Ozlü (Trabzon, Turkey)
|   |
Prognosis factors of recurrent pulmonary thromboembolism
J. Zhang, Q. L. Xie, H. Tan (Yinchuang, China)
| |
An overview of thrombolytic treatment for pulmonary embolism: A single center experience
H. Selimoglu Sen, O. Abakay, C. Sezgi, S. Yilmaz, M. Taylan, H. Kaya, A. C. Tanrikulu, A. Abakay (Diyarbakir, Turkey)
| |
Clinical phenotypes in pulmonary emboli identified by cluster analysis
E. Bulcun, D. çimen, A. Ekici, M. Ekici, P. Yildiz Gulhan (Kirikkale, Turkey)
| |
Endothelial dysfunction in pulmonary embolism: Neutrophil-lymphocyte and platelet-lymphocyte ratio
E. Kurtipek, Z. Büyükterzi, M. Büyükterzi, M. Sertaç Alpaydin, T. Tahir Bekci, B. Akin, S. Erdem (Konya, Turkey)
| |
Rivaroxaban for treatment of venous thromboembolism. A real-life perspective in 103 patients
R. Sanchez-Oro-Gomez, L. Jara-Palomares, R. Morillo-Guerrero, T. Elias-Hernandez, M. Ferrer-Galvan, M. Asensio-Cruz, R. Otero-Candelera (Seville, Spain)
| |
Serum apelin 13 levels in patients with pulmonary embolism
H. Selimoglu Sen, I. Kaplan, O. Abakay, C. Sezgi, S. Yilmaz, M. Taylan, A. C. Tanrikulu, A. Abakay (Diyarbakir, Turkey)
| |
Venous thromboembolic disease (VTD) associated with inflammatory bowel disease (IBD): RIETE´s experience
J. L. Lobo Bersitain, J. A. García Fuertes, E. Miranda Serrano, I. Casado Moreno, J. Luque Pinilla, M. Barrón Medrano, M. Monreal, RIETE Group (Vitoria-Gasteiz, Granada, Madrid, Logroño, Spain)
| |
Do persistent perfusion defects predict late recurrences in pulmonary embolism?
L. Villari, R. Pancani, L. Marconi, E. Mariancini, F. Aquilini, A. Celi, A. Palla (Pontedera, Pisa, Italy)
| |
Integration of the level of D-dimer (D-d) with Wells criteria to improve the prediction of pulmonary embolism (PE) before CT angiography of the lung (CTAL)
O. Derzac, S. Croiteru, Y. Dotan, E. Schiff, A. Oliven (Haifa, Israel)
| |
Warfarin-associated intracranial hemorrhage during anticoagulation therapy
S. M. Koo, Y. K. Kim, S. T. Uh, K. U. Kim (Seoul, Republic Of Korea)
| |
Risk stratification in submassive pulmonary embolism via alveolar-arterial oxygen gradient
O. Ince, S. Findik, N. Altintas, M. Sariaydin (Samsun, Tekirdag, Turkey)
| |
Is a complete blood cell count useful in determining the prognosis of pulmonary embolism?
H. Selimoglu Sen, O. Abakay, A. C. Tanrikulu, C. Sezgi, M. Taylan, A. Abakay, H. Kaya, A. Senyigit (Diyarbakir, Turkey)
| |
Tinzaparin and vitamin K antagonist (VKA) use in patients with cancer associated venous thromboembolism (VTE): A cohort study
E. Noel-Savina, O. Sanchez, R. Descourt, M. Andre, G. Meyer, C. Leroyer, F. Couturaud (Brest, Paris, France)
| |
Alteration of factors associated with coagulation in provoked pulmonary embolism
W. I. Choi (Daegu, Republic Of Korea)
| |
Does Wells score documentation really prevent excessive CTPA requests in a teaching hospital? A retrospective study in 800 patients
P. Rajagopalan, J. Wingfield Digby, C. Lee, R. D. Barker (London, United Kingdom)
| |
Measurement of cardiac troponin identifies patients with moderate to large pulmonary emboli and right ventricular strain
J. Andrews, W. MacNee, J. Murchison (Edinburgh, United Kingdom)
| |
Is serum cystatin C a predictor of acute pulmonary thromboembolism in patients with normal renal function?
N. Tutar, N. A. Kemik, I. Yilmaz, C. Yazici, F. Elmali, H. Buyukoglan, A. Kanbay, A. Dogan, F. S. Oymak, I. Gulmez, R. Demir (Kayseri, Istanbul, Turkey)
| |
Electrocardiographic abnormalities in patients with low or moderate risk pulmonary embolism: Prevalence and association with PO2 /FiO2 ratio
C. Kampolis, A. Loukeri, A. Aiginitou, D. Papapetrou, A. Tzagkaraki, P. Kythreotis, P. Loukeri, D. Veldekis (Athens, Greece)
| |